Kazia Therapeutics (NASDAQ: KZIA) can sell up to $80M in ADSs

Rhea-AI Filing Summary

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement updating its at-the-market offering program of American Depositary Shares (ADSs) under its Form F-3 shelf. The company reduced the maximum aggregate offering price of ADSs that may be offered under its Sales Agreement with Leerink Partners LLC from $100,000,000 to $80,000,000, including ADSs previously sold. As of this supplement, Kazia has sold 510,000 ADSs for approximately $5,106,516 under the agreement. Each ADS represents 500 ordinary shares, and the ADSs trade on the Nasdaq Capital Market under the symbol KZIA, with a closing price of $16.90 per ADS on August 27, 2026.

Key Figures

Maximum aggregate offering price (current ATM capacity): $80,000,000 Previous maximum aggregate offering price: $100,000,000 ADSs sold to date under Sales Agreement: 510,000 ADSs +3 more

6 metrics

Maximum aggregate offering price (current ATM capacity) $80,000,000 Aggregate offering price of ADSs that may be offered under the Sales Agreement, including previously sold ADSs

Previous maximum aggregate offering price $100,000,000 Initial registered amount of ADSs for sale under the Sales Agreement in the prior prospectus

ADSs sold to date under Sales Agreement 510,000 ADSs ADSs sold pursuant to the Sales Agreement as of the date of the prospectus supplement

Aggregate offering price of ADSs sold $5,106,516 Total offering price received for 510,000 ADSs sold under the Sales Agreement

ADS to ordinary share ratio 1 ADS = 500 ordinary shares Each American Depositary Share represents 500 ordinary shares, no par value

Recent ADS closing price $16.90 per ADS Closing price on the Nasdaq Capital Market on August 27, 2026

Key Terms

American Depositary Shares, at-the-market, Sales Agreement, foreign private issuer, +1 more

5 terms

American Depositary Shares financial

"offering, issuance and sale by us of our American Depositary Shares, or ADSs, each representing 500 ordinary shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

at-the-market financial

"may be issued and sold under the Sales Agreement ... as sales agent, or the ATM Facility"

"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.

Sales Agreement financial

"may be issued and sold under the Sales Agreement, dated March 17, 2026, or the Sales Agreement, by and between us and Leerink Partners LLC"

A sales agreement is a written contract that sets out the terms for selling goods, services, or assets, specifying price, delivery, payment schedule and responsibilities of each side. For investors it matters because it creates a predictable stream of revenue or cash obligations, clarifies timing and risk, and can change a company’s value or forecasts much like a signed order turns a customer’s verbal intent into a firm commitment.

foreign private issuer regulatory

"We are a “foreign private issuer” under the federal securities laws and, as such, are subject to reduced public company disclosure standards"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

prospectus supplement regulatory

"This prospectus supplement amends and supplements the information in the prospectus, dated March 27, 2026"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Offering Details

ATM

Offering

Offering Type ATM

FAQ

What change did KZIA make to its at-the-market offering capacity in this 424B5?

Kazia Therapeutics reduced the maximum aggregate offering price of American Depositary Shares under its Sales Agreement with Leerink Partners from $100,000,000 to $80,000,000, including ADSs previously sold through the facility.

How many KZIA ADSs have been sold under the Sales Agreement so far?

Kazia Therapeutics has sold 510,000 ADSs under the Sales Agreement, for an aggregate offering price of approximately $5,106,516, as of the date of the prospectus supplement.

What securities are covered by KZIA’s updated 424B5 prospectus supplement?

The supplement covers an at-the-market offering of up to $80,000,000 of American Depositary Shares (ADSs), each ADS representing 500 ordinary shares of Kazia Therapeutics Limited, to be sold from time to time through Leerink Partners LLC.

On which market are KZIA ADSs listed and what was the recent price?

Kazia Therapeutics’ ADSs are listed on the Nasdaq Capital Market under the symbol KZIA. On August 27, 2026, the closing price of the ADSs was $16.90 per ADS.

Does KZIA receive proceeds from sales under this ATM facility?

Yes. The prospectus supplement describes an at-the-market offering of ADSs issued and sold by Kazia Therapeutics from time to time through Leerink Partners under the Sales Agreement, so Kazia is the issuer receiving proceeds from these sales.

What is Kazia Therapeutics’ regulatory status mentioned in the supplement?

Kazia Therapeutics states that it is a “foreign private issuer” under U.S. federal securities laws and is therefore subject to reduced public company disclosure standards for this prospectus supplement and future filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 08:45 AM Accepted by SEC EDGAR 08/28/2026 - 06:08 AM Learn about SEC filing dates

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-294392

PROSPECTUS SUPPLEMENT

(To prospectus dated March 27, 2026)

Kazia Therapeutics Limited

Up to $80,000,000 of
American Depositary Shares Representing Ordinary Shares

This prospectus supplement amends and supplements the information in the prospectus, dated March 27, 2026, filed as a part of our registration statement on Form F-3 (File No. 333-294392), or the Registration Statement, as supplemented by our prospectus supplement, dated March 27, 2026, or the Prior Prospectus, relating to the offering, issuance and sale by us of our American Depositary Shares, or ADSs, each representing 500 ordinary shares, no par value, from time to time that may be issued and sold under the Sales Agreement, dated March 17, 2026, or the Sales Agreement, by and between us and Leerink Partners LLC, or Leerink Partners, as sales agent, or the ATM Facility. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.

We are filing this prospectus supplement to amend the Prior Prospectus to reduce the maximum aggregate offering price of ADSs that may be offered, issued and sold under the Sales Agreement from $100,000,000 to $80,000,000, including the ADSs previously sold pursuant to the Sales Agreement. Under the Prior Prospectus, we initially registered up to $100,000,000 of ADSs for sale under the Sales Agreement. As of the date of this prospectus supplement, we have sold 510,000 ADSs having an aggregate offering price of approximately $5,106,516 pursuant to the Sales Agreement. In accordance with the terms of the Sales Agreement, we may offer and sell ADSs having an aggregate offering price of up to $80,000,000, less the aggregate offering price of ADSs previously sold under the Sales Agreement, from time to time through Leerink Partners.

The ADSs are listed on the Nasdaq Capital Market under the symbol “KZIA.” On August 27, 2026, the closing price of the ADSs on the Nasdaq Capital Market was $16.90 per ADS.

We are a “foreign private issuer” under the federal securities laws and, as such, are subject to reduced public company disclosure standards for this prospectus supplement and future filings. See “Prospectus Supplement Summary—Implications of Being a Foreign Private Issuer” in the Prior Prospectus for additional information.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-3 of the Prior Prospectus and on page 3 of the accompanying prospectus and in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of certain factors you should consider before investing in our securities.

Neither the U.S. Securities and Exchange Commission nor any state or other foreign securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

Leerink Partners

The date of this prospectus supplement is August 28, 2026